![logo](/logos/ELEV.webp)
Elevation Oncology, Inc.
NASDAQ:ELEV
0.63 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Elevation Oncology, Inc. |
Symbool | ELEV |
Munteenheid | USD |
Prijs | 0.625 |
Beurswaarde | 36,941,750 |
Dividendpercentage | 0% |
52-weken bereik | 0.363 - 5.83 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Joseph J. Ferra Jr. |
Website | https://elevationoncology.com |
An error occurred while fetching data.
Over Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)